PT  - JOURNAL ARTICLE
AU  - Ashley V. Makela
AU  - Melissa A. Schott
AU  - Cody Madsen
AU  - Emily Greeson
AU  - Christopher H. Contag
TI  - Magnetic particle imaging of magnetotactic bacteria as living contrast agents is improved by altering magnetosome structures
AID  - 10.1101/2021.12.03.471101
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.12.03.471101
4099  - http://biorxiv.org/content/early/2021/12/04/2021.12.03.471101.short
4100  - http://biorxiv.org/content/early/2021/12/04/2021.12.03.471101.full
AB  - Iron nanoparticles used as imaging contrast agents can help differentiate between normal and diseased tissue, or track cell movement and localize pathologies. Magnetic particle imaging (MPI) is an imaging modality that uses the magnetic properties of iron nanoparticles to provide specific, quantitative and sensitive imaging data. MPI signals depend on the size, structure and composition of the nanoparticles; MPI-tailored nanoparticles have been developed by modifying these properties. Magnetotactic bacteria produce magnetosomes which mimic synthetic nanoparticles, and thus comprise a living contrast agent in which nanoparticle formation can be modified by mutating genes. Specifically, genes that encode proteins critical to magnetosome formation and regulation, such as mamJ which helps with filament turnover. Deletion of mamJ in Magnetospirillum gryphiswaldense, MSR-1 led to clustered magnetosomes instead of the typical linear chains. Here we examined the effects of this magnetosome structure and revealed improved MPI signal and resolution from clustered magnetosomes compared to linear chains. Bioluminescent MSR-1 with the mamJ deletion were injected intravenously into tumor-bearing and healthy mice and imaged using both in vivo bioluminescence imaging (BLI) and MPI. BLI revealed the location and viability of bacteria which was used to validate localization of MPI signals. BLI identified the viability of MSR-1 for 24 hours and MPI detected iron in the liver and in multiple tumors. Development of living contrast agents offers new opportunities for imaging and therapy by using multimodality imaging to track the location and viability of the therapy and the resulting biological effects.Competing Interest StatementThe authors have declared no competing interest.